SCHEMBL5216491

SCHEMBL5216491

COc1ccc(NC=O)c(CO)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OR51E2 Q9H255 1/20 0.51
ALDH1A1 P00352 2/20 0.43
HSD17B10 Q99714 1/20 0.41
CYP1A2 P05177 2/20 0.40
ERN1 O75460 1/20 0.40
CYP1A1 P04798 1/20 0.40
CYP1B1 Q16678 1/20 0.40
TRIM24 O15164 1/20 0.40
TYR P14679 1/20 0.40
TRIM33 Q9UPN9 1/20 0.40
KDM4E B2RXH2 1/20 0.40
APLNR P35414 1/20 0.40
F10 P00742 1/20 0.40
MAPT P10636 1/20 0.39
ADRB2 P07550 2/20 0.39
ADRB1 P08588 2/20 0.39
DRD2 P14416 2/20 0.39
PGR P06401 1/20 0.39
SLC6A4 P31645 1/20 0.39
ADRA1A P35348 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9947244 0.87 OR51E2 (0.50) OR51E2ALDH1A1HSD17B10CYP1A2CYP1A1
SCHEMBL1674190 0.78 MEN1 (0.40) ALDH1A1CYP1A2KDM4EPTGS2CYP2C19
SCHEMBL31432473 0.78 TRIM24 (0.56) OR51E2ALDH1A1CYP1A2ERN1CYP1A1
SCHEMBL25140462 0.78 ALDH1A1 (0.43) ALDH1A1HSD17B10KDM4EAPLNRADRA1A
SCHEMBL2203559 0.76 ALDH1A1 (0.56) OR51E2ALDH1A1CYP1A2CYP1A1CYP1B1
SCHEMBL5597294 0.76 GAA (0.53) OR51E2ALDH1A1CYP1A2ERN1CYP1A1
SCHEMBL2303908 0.75 TRIM24 (0.61) ALDH1A1HSD17B10CYP1A2ERN1CYP1A1
SCHEMBL5223370 0.75 ERN1 (0.56) OR51E2ALDH1A1CYP1A2ERN1CYP1A1
SCHEMBL2095308 0.75 OR51E2 (0.48) OR51E2ALDH1A1CYP1A2ERN1CYP1A1
SCHEMBL11322262 0.73 KMT2A (0.48) OR51E2ALDH1A1HSD17B10CYP1A2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456197-B1 PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 GRUENENTHAL GMBH (DE) 2007-02-28 EP disclosed
US-7183274-B2 Piperidine-2,6-diones heterocyclically substituted in the 3-position GRUENENTHAL GMBH (DE) 2007-02-27 US disclosed
US-20050020581-A1 Piperidine-2,6-diones heterocyclically substituted in the 3-position GRUENENTHAL GMBH (DE) 2005-01-27 US disclosed
EP-1456197-A1 PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 Grünenthal GmbH (DE) 2004-09-15 EP disclosed
WO-2003053956-A1 PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 Grünenthal GmbH (DE) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020581-A1 Piperidine-2,6-diones heterocyclically substituted in the 3-position DPYD, CYP2D6, DHPS OR51E2 2773/4885ALDH1A1 128/4885HSD17B10 2072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.